Ponatinib for chronic myeloid leukemia

New England Journal of Medicine

Volumn 367, Issue 22, 2012, Pages 2148-2149

  Goldman, John M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; CD135 ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IMATINIB; PONATINIB;

AMINO ACID SUBSTITUTION; BCR ABL GENE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; EDITORIAL; ENZYME ACTIVITY; FUSION GENE; HUMAN; MOLECULAR CLONING; MOLECULAR MODEL; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PANCREATITIS; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SEQUENCE ANALYSIS;

EID: 84869986954     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1210796     Document Type: Editorial

References (8)

1. Druker BJ, Tamura S, Buchduner E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
2. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80. (Pubitemid 32743979)
3. Khorashad JS, de Lavallade H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008;26:4806-13.
4. Huang W-S, Metcalf CA, Sundaramoorthi R, et al. Discovery of 3-[2-(imidazo[1,2b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 2010;53:4701-19.
5. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401-12.
6. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome - positive leukemias. N Engl J Med 2012;367:2075-88.
7. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. PACE: a pivotal phase 2 trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315 mutation. Presented at the 17th Congress of the European Hematology Association, Amsterdam, June 14-17, 2012. abstract.
8. Gozgit JM, Wong MJ, Wardwell S, et al. Potent activity of ponatinib in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther 2011;10:1028-35.